HUTCHMED (China) Limited said its subsidiary, HUTCHMED Limited, entered into an exclusive development and license agreement with a subsidiary of GSK plc that grants the GSK subsidiary worldwide rights, excluding Mainland China, Hong Kong, Macau and Taiwan, to develop and commercialize HMPL-A830, according to GlobeNewswire PE. The agreement includes a US$110 million upfront payment and potential development, regulatory and commercial milestone payments, for up to a total of US$1.295 billion, and royalties on net sales, according to GlobeNewswire PE.
Territory rights and initial indication focus
HUTCHMED said the GSK subsidiary will hold worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830. HUTCHMED said clinical development will initially focus on colorectal, pancreatic and lung cancer indications.
The announcement was issued from Hong Kong and Florham Park, N.J. on Sept. 03, 2026, and identified HUTCHMED (China) Limited as listed on Nasdaq/AIM under HCM and on HKEX under 13.
Economics and responsibilities split
The agreement includes a US$110 million upfront payment and potential development, regulatory and commercial milestone payments, for up to a total of US$1.295 billion, and royalties on net sales, according to GlobeNewswire PE. Under the terms of the agreement, HUTCHMED Limited will be responsible for the global phase I development program.
HUTCHMED said the phase I program is expected to start in the second half of 2026 and listed a clinicaltrials.gov identifier of NCT07718581. HUTCHMED said the GSK subsidiary will be responsible for all subsequent clinical development and commercialization activities outside of Mainland China, Hong Kong, Macau and Taiwan.
Asset description and platform notes
HUTCHMED described HMPL-A830 as a first-in-class drug candidate and an Antibody-Targeted Therapy Conjugate (ATTC) that comprises a highly selective and potent Kirsten rat sarcoma (KRAS) small molecule inhibitor payload conjugated to an anti-epidermal growth factor receptor (EGFR) antibody, according to GlobeNewswire PE. HUTCHMED said an ATTC enables tumor-selective activity of potent, cell-killing payloads by leveraging antibody-guided therapy.
HUTCHMED said colorectal, lung, and pancreatic cancers have the highest incidence of patients with KRAS-altered tumors, who often lack a safe and durable KRAS therapy. HUTCHMED said HMPL-A830 is designed to deliver a KRAS inhibitor directly to EGFR-expressing tumors while simultaneously blocking EGFR and KRAS signaling to enhance efficacy, durability, and tolerability.
HUTCHMED quoted Mr Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED, as saying the company is “proud to work with GSK” and that both companies are “committed to developing innovative new cancer medicines to address significant unmet medical needs worldwide.” Mr Cheng said HUTCHMED’s ATTCs combine antibodies with proprietary small-molecule inhibitor payloads to deliver dual mechanisms of action, and said HMPL-A830 is HUTCHMED’s third drug candidate from these novel payload platforms and the first from its platform to be licensed to a global partner, following two candidates that have entered clinical development.
Company webcast timing
HUTCHMED said it webcasts today at 4:30 p.m. HKT in Chinese (Putonghua) and at 7:30 a.m. EDT, 12:30 p.m. BST, and 7:30 p.m. HKT in English.
Widely known context: licensing agreements in biopharma typically include an upfront payment plus contingent milestone payments tied to development, regulatory, and commercial events. Widely known context: royalties on net sales generally provide the licensor with a percentage-based payment stream if a product reaches market and generates revenue.
